Lupin Limited · NSE:LUPIN
Lupin — Q2 FY2023 Earnings Presentation
17 slides from Lupin's earnings presentation, Nov 10, 2022
Slide 1: Cover letter to BSE and NSE
November 10, 2022 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Investor Presentation Q2 FY2022-23. Pursuant to Regulati
Slide 2: |
|
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Financial Results Review
Financial Results Review 3
Slide 5: Q2 FY23 Snapshot
Q2 FY23 Snapshot Important developments Commercial Sales (In INR mn and %) • Signed agreement to acquire Two Inhalation Brands from Sunovion North America, • Launched Generic Suprep® Bowel Prep Kit in the United India, 13,295, 33% States 15,841, 39% Mr. Nilesh.D.Gupta Total Managing Director • Lupin
Slide 6: P&L Highlights- Q2 FY23
P&L Highlights- Q2 FY23 QoQ YoY Amount in INR mn Q2FY23 % of Sales Q1FY23 % of Sales Q2FY22 % of Sales Growth Growth Sales 40,912 100.0% 36,040 100.0% 13.5% 40,034 100.0% 2.2% Other operating income 543 1.3% 1,398 3.9% -61.2% 879 2.2% -38.2% Total revenue 41,455 101.3% 37,438 103.9% 10.7% 40,913 102
Slide 7: India Business Update
Q2FY23 38.7% YoY QoQ % of Sales India Business Update 2.6% 6.2% India Quarterly Sales (INR bn) Lupin continues to maintain leadership in Chronic 15.8 CAGR MAT SEP’17 – ’22 Lupin Rank1 15.4 14.7 14.9 Therapy 13.5 Market Lupin MAT SEP’17 MAT SEP’22 Acute 10% 7% 12 14 Chronic 12% 12% 4 4 Cardiac 11% 10
Slide 8: North America
Q2FY23 32.5% YoY QoQ % of Sales North America -7.0% 31.6% US Generics: An established leader Managing our transition to Complex Generics US quarterly sales ($ mn) 46 21.3% 110 202 200 184 181 Number of Albuterol Gx Number of 159 products Market share1 Products Top 3 by 150 121 Market leader1 Market
Slide 9: Other Markets
Other Markets • Germany: EUR 9.9 mn sales in Q2 FY23 versus EUR 7.9 mn in Q2 FY22 EU5 • Developed Tempil® and men’s health products portfolio contributed to 25% of YoY revenue growth in EMEA Q2 FY23 • 8th largest generics player1; Market leader in CVS space South Africa • ZAR 358.3 mn sales in Q2 FY
Slide 10: Key Financial Metrics
Key Financial Metrics R&D (INR mn) Capex (INR mn) 2,787 3,546 3,442 3,478 3,376 1,577 1,613 3,300 1,451 1,540 Q2FY22 Q3FY22 Q4FY22 Q1 FY23 Q2 FY23 Q2FY22 Q3FY22 Q4FY22 Q1 FY23 Q2 FY23 R&D (% of Sales) Net debt/ Equity 9.6% 0.25 0.21 8.9% 0.18 8.7% 0.16 8.2% 8.3% (0.01) Q2FY22 Q3FY22 Q4FY22 Q1 FY23 Q
Slide 11: ESG Outlook
ESG OUTLOOK
Slide 12: ESG: Targets and Action
ESG: Targets and Action Environment Supply chain Social Governance Project Plan for Rooftop Installation by FY 2023: Implementation of Lupin’s Third- Incorporated claw back policy in Party Code of Conduct for all CSR target: Plant 1,600,000 Nomination & Remuneration suppliers and vendors by 2022 tre
Slide 13: Lupin at a Glance
¥ = of LUPIN ATA | \ POR cance
Slide 14: Lupin Today
Lupin Today Financial Metrics Globally Major Markets Market Cap (1,2) US$ 3.87 bn 10th 6th 3rd 6th Largest Generic Largest Indian Largest in India Pharma Revenue (FY22)(3) US$ 2.2 bn company Pharma the US Market Rank5 (by sales4) (by global sales4) (by prescriptions5) EBITDA (FY22)(3) US$ 311 mn Net
Slide 15: Strategic Vision Update: A Global Pharma Company Focused on our Core Growth Platforms
Strategic Vision Update: A Global Pharma Company Focused on our Core Growth Platforms India Complex Gx Global Developed Gx Region Platforms Market Footprint Achieving substantially Substantial and scaled Operational efficiency above market growth product platforms from Global presence Organic and in
Slide 16: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Vinita Gupta, named among India’s 20 Most Influential Women in Healthcare by BW Healthcare World • Rajendra Chunodkar named among the Game Changers in Manufacturing by Fortune India • Lupin wins the prestigious ATD (Association of Talent Development) BEST Award • Lupin
Slide 17: Thank you
Thank you REGISTERED OFFICE youtube.com/c/LupinGlobal twitter.com/LupinGlobal 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai – 400 055. India, linkedin.com/company/lupin/ Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com facebook.com/LupinWorld/